EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma

Don Eslin, Peter E Zage, Genevieve Bergendahl iD, Elizabeth Lewis, William Roberts, Jacqueline Kraveka, Deanna Mitchell, Michael S Isakoff, Jawhar Rawwas, Randal K Wada, Mark Fluchel, Valerie I Brown und 7 weitere

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34569 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Don Eslin und 18 weiteren Autor:innen. Beteiligte Einrichtung: St Joseph's Children's Hospital, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Medulloblastoma, Neuroblastoma, Cerebellar Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beat NB Foundation, Brooke's Blossoming Hope for Childhood Cancer Foundation, Ethan's Rodeo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Children with relapsed/refractory (R/R) neuroblastoma (NB) and medulloblastoma (MB) have poor outcomes. We evaluated the efficacy of nifurtimox (Nfx) in a clinical trial for children with R/R NB and MB. Subjects were divided into three strata: first relapse NB, multiply R/R NB, and R/R MB. All patients received Nfx (30 mg/kg/day divided TID daily), Topotecan (0.75 mg/m 2 /dose, days 1‐5) and Cyclophosphamide (250 mg/m 2 /dose, days 1‐5) every 3 weeks. Response was assessed after every two courses using International Neuroblastoma Response Criteria and Response Evaluation Criteria in Solid Tumors (RECIST) criteria. One hundred and twelve eligible patients were enrolled with 110 evaluable for safety and 76 evaluable for response. In stratum 1, there was a 53.9% response rate (CR + PR), and a 69.3% total benefit rate (CR + PR + SD), with an average time on therapy of 165.2 days. In stratum 2, there was a 16.3% response rate, and a 72.1% total benefit rate, and an average time on study of 158.4 days. In stratum 3, there was a 20% response rate and a 65% total benefit rate, an average time on therapy of 105.0 days. The most common side effects included bone marrow suppression and reversible neurologic complications. The combination of Nfx, topotecan and cyclophosphamide was tolerated, and the objective response rate plus SD of 69.8% in these heavily pretreated populations suggests that this combination is an effective option for patients with R/R NB and MB. Although few objective responses were observed, the high percentage of stabilization of disease and prolonged response rate in patients with multiply relapsed disease shows this combination therapy warrants further testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaNeuroblastomaCerebellar NeoplasmsChildHumansTopotecanNifurtimoxNeoplasm Recurrence, LocalCyclophosphamideAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

medulloblastomaneuroblastomanifurtimox

Substanzen

TopotecanNifurtimoxCyclophosphamide

Autor:innen und Institutionen

  • St Joseph's Children's Hospital, Tampa, Florida, USA.
  • Department of Pediatrics, Division of Hematology-Oncology, University of California San Diego, La Jolla, California, USA.
  • Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, California, USA.
  • Levine Children's Hospital, Atrium Health, Charlotte, North Carolina, USA.
  • Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Genevieve Bergendahl, Giselle L Saulnier Sholler

Förderung

  • Beat NB Foundation
  • Brooke's Blossoming Hope for Childhood Cancer Foundation
  • Ethan's Rodeo
  • Jesse Heikkila Foundation
  • Lillie's Friends Foundation
  • Max's Ring of Fire
  • Meryl and Charles Witmer Foundation
  • Owen Moscone Foundation

Zitieren

APA

Eslin, D., Zage, P. E., Bergendahl, G., Lewis, E., Roberts, W., Kraveka, J., Mitchell, D., Isakoff, M. S., Rawwas, J., Wada, R. K., Fluchel, M., Brown, V. I., Ginn, K., Higgins, T., BeeravallyNagulapally, A., Dykema, K., Hanna, G., Ferguson, W., & Saulnier Sholler, G. L. (2023). A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. International Journal of Cancer. https://doi.org/10.1002/ijc.34569

Vancouver

Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, et al. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. International Journal of Cancer. 2023. doi:10.1002/ijc.34569

BibTeX
@article{Eslin2023,
  author = {Eslin, Don and Zage, Peter E and Bergendahl, Genevieve and Lewis, Elizabeth and Roberts, William and Kraveka, Jacqueline and Mitchell, Deanna and Isakoff, Michael S and Rawwas, Jawhar and Wada, Randal K and Fluchel, Mark and Brown, Valerie I and Ginn, Kevin and Higgins, Timothy and BeeravallyNagulapally, Abhinav and Dykema, Karl and Hanna, Gina and Ferguson, William and Saulnier Sholler, Giselle L},
  title = {A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34569}
}
Kostenlos starten →